251 related articles for article (PubMed ID: 1096575)
1. Dopaminergic agonist effects on Parkinsonian clinical features and brain monamine metabolism.
Rinne UK; Sonninen V; Marttila R
Adv Neurol; 1975; 9():383-92. PubMed ID: 1096575
[TBL] [Abstract][Full Text] [Related]
2. [Piribedil, dopaminergic agonist. Prolonged clinical and electrophysiological study in 60 parkinsonian patients (author's transl)].
Truelle JL; Chanelet J; Bastard J; Six P; Emile J
Nouv Presse Med; 1977 Oct; 6(33):2987-90. PubMed ID: 22844
[TBL] [Abstract][Full Text] [Related]
3. Dopaminergic mechanisms in patients with extrapyramidal disease.
Chase TN; Shoulson I
Adv Neurol; 1975; 9():359-66. PubMed ID: 1146660
[No Abstract] [Full Text] [Related]
4. Brain dopamine turnover and the relief of parkinsonism.
Rinne UK; Marttila R; Sonninen V
Arch Neurol; 1977 Oct; 34(10):626-9. PubMed ID: 907536
[TBL] [Abstract][Full Text] [Related]
5. Brain dopamine turnover and the relief of parkinsonism.
Rinne UK; Sonninen V; Marttila R
Adv Exp Med Biol; 1977; 90():267-75. PubMed ID: 930747
[TBL] [Abstract][Full Text] [Related]
6. [Piribedil in the treatment of Parkinson disease (author's transl)].
Nardini M; Sciannandrone R; Fieschi C; De Simone G
Riv Patol Nerv Ment; 1975; 96(2):103-10. PubMed ID: 778998
[TBL] [Abstract][Full Text] [Related]
7. [The effectiveness and tolerance of piribedil as adjunct therapy to levodopa in patients with Parkinson's disease: a nine month follow up].
Salazar Tortolero G; Wix Ramos R; Salazar Aladrén P; Jiménez León JC
Rev Neurol; 2004 Apr 16-30; 38(8):715-9. PubMed ID: 15122540
[TBL] [Abstract][Full Text] [Related]
8. Indications of piribedil in L-DOPA-treated parkinsonian patients: physiopathologic implications.
Rondot P; Bathien N; Dumas JL
Adv Neurol; 1975; 9():373-81. PubMed ID: 1096574
[No Abstract] [Full Text] [Related]
9. Piribedil--an oral dopamine agonist for treatment of Parkinson's disease.
Sweet RD; Wasterlain C; McDowell FH
Trans Am Neurol Assoc; 1974; 99():258-60. PubMed ID: 4463553
[No Abstract] [Full Text] [Related]
10. Piribedil (ET 495) in the treatment of Parkinson's disease combined with amantadine or levodopa.
Callaghan N; Fitzpatrick E; O'Mahony JB
Acta Neurol Scand; 1975 Sep; 52(3):179-86. PubMed ID: 1098359
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study.
Ziegler M; Castro-Caldas A; Del Signore S; Rascol O
Mov Disord; 2003 Apr; 18(4):418-25. PubMed ID: 12671949
[TBL] [Abstract][Full Text] [Related]
12. Piribedil therapy in Parkinson's disease. Use of the drug in the retard form.
Mentenopoulos G; Katsarou Z; Bostantjopoulou S; Logothetis J
Clin Neuropharmacol; 1989 Feb; 12(1):23-8. PubMed ID: 2713865
[TBL] [Abstract][Full Text] [Related]
13. 14C-homovanillic acid in the cerebrospinal fluid of parkinsonian patients after intravenous 14C-L-dopa.
Extein I; Van Woert M; Roth RH; Bowers MB
Biol Psychiatry; 1976 Apr; 11(2):227-32. PubMed ID: 971447
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study.
Suwantamee J; Nidhinandana S; Srisuwananukorn S; Laptikultham S; Pisarnpong A; Chankrachang S; Bundhukul A
J Med Assoc Thai; 2004 Nov; 87(11):1293-300. PubMed ID: 15825702
[TBL] [Abstract][Full Text] [Related]
15. Actions of dopaminergic agonists in parkinsonism.
McDowell FH; Sweet R
Adv Neurol; 1975; 9():367-71. PubMed ID: 1096573
[No Abstract] [Full Text] [Related]
16. Clinical and pharmacological evaluation of the effects of piribedil in patients with parkinsonism.
McLellan DL; Chalmers RJ; Johnson RH
Acta Neurol Scand; 1975 Jan; 51(1):74-82. PubMed ID: 1091122
[TBL] [Abstract][Full Text] [Related]
17. Piribedil: its synergistic effect in multidrug regimens for parkinsonism.
Feigenson JS; Sweet RD; McDowell FH
Neurology; 1976 May; 26(5):430-3. PubMed ID: 944394
[TBL] [Abstract][Full Text] [Related]
18. Action of piribedil in Parkinson's disease: I.V. test and oral treatment.
Emile J; Chanelet J; Truelle JL; Bastard J
Adv Neurol; 1975; 9():409-13. PubMed ID: 1096577
[No Abstract] [Full Text] [Related]
19. The dopamine agonist piribedil with L-DOPA improves attentional dysfunction: relevance for Parkinson's disease.
Turle-Lorenzo N; Maurin B; Puma C; Chezaubernard C; Morain P; Baunez C; Nieoullon A; Amalric M
J Pharmacol Exp Ther; 2006 Nov; 319(2):914-23. PubMed ID: 16920993
[TBL] [Abstract][Full Text] [Related]
20. Dopaminergic nervous transmission in Parkinson's disease.
Rinne UK; Sonninen V; Riekkinen P; Laaksonen H
Med Biol; 1974 Jun; 52(3):208-17. PubMed ID: 4371255
[No Abstract] [Full Text] [Related]
[Next] [New Search]
